

NANOBAC PHARMACEUTICALS INC  
Form 10QSB  
November 13, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 10-QSB  
QUARTERLY REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

---

For the Quarter Period Ended  
**September 30, 2006**

---

**Nanobac Pharmaceuticals, Incorporated**  
(Exact name of registrant as specified in its charter)

**Florida**  
(State or Other Jurisdiction  
of Incorporation)

**0-24696**  
(Commission File Number)

**59-3248917**  
(I.R.S. Employer  
Identification Number)

**4730 North Habana Avenue, Suite 205, Tampa, Florida 33614**  
(Address of Principal Executive Office) (Zip Code)

**(813) 264-2241**  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for a shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Rule 12b-2 of the Act):

Yes  No

The number of shares issued and outstanding of the Registrant's Common Stock, no par value, as of November 6, 2006 was 193,973,426.

---

**NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES****PART I - FINANCIAL INFORMATION****Item 1: Financial Statements**

Condensed Consolidated Balance Sheets as of September 30, 2006 (unaudited) and December 31, 2005	3
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2006 and 2005 (unaudited)	4
Condensed Consolidated Statements of Changes in Stockholders' Equity for the nine months ended September 30, 2006 (unaudited)	5
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2006 and 2005 (unaudited)	6
Notes to the Condensed Consolidated Financial Statements	7

<b>Item 2:</b>	<b>Management's Discussion and Analysis of Financial Condition and Results of Operations</b>	11
----------------	--	----

<b>Item 3:</b>	<b>Controls and Procedures</b>	21
----------------	--------------------------------	----

**PART II - OTHER INFORMATION**

<b>Item 1:</b>	<b>Legal Proceedings</b>	22
----------------	--------------------------	----

<b>Item 2:</b>	<b>Unregistered Sales of Equity Securities and Use of Proceeds</b>	23
----------------	--	----

<b>Item 3:</b>	<b>Defaults Upon Senior Securities</b>	24
----------------	--	----

<b>Item 4:</b>	<b>Submission of Matters to a Vote of Security Holders</b>	24
----------------	--	----

<b>Item 5:</b>	<b>Other Information</b>	24
----------------	--------------------------	----

<b>Item 6:</b>	<b>Exhibits</b>	24
----------------	-----------------	----

NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES  
CONDENSED CONSOLIDATED  
BALANCE SHEETS

(UNAUDITED)

(Unaudited)

September 30, 2006

December 31, 2005

**ASSETS****CURRENT ASSETS**

Cash	\$	110,710	\$	8,975
Account receivable		9,052		3,283
Inventory		112,108		117,280
Prepaid expenses		37,555		43,725
<b>Total current assets</b>		<b>269,425</b>		<b>173,263</b>

**FURNITURE AND EQUIPMENT, less**

accumulated depreciation

of \$96,236 at September 30, 2006 and \$131,163

at December 31, 2005

66,322

106,952

**OTHER ASSETS**

Security deposits 74,168 20,695

Intangible assets, less accumulated amortization

of \$1,169,811 at September 30, 2006 and

\$1,539,621 at December 31, 2005

4,073,231

5,053,421

Goodwill

3,615,393

3,615,393

**Total other assets**

7,762,792

8,689,509

**TOTAL ASSETS**

\$

8,098,539

\$

8,969,724

**LIABILITIES AND STOCKHOLDERS' EQUITY****CURRENT LIABILITIES**

Accounts payable	\$	326,953	\$	313,932
Accrued compensation		211,065		462,658
Accrued expenses		368,379		376,874
Short-term notes payable		-		50,843
Other liabilities		9,068		29,425
Related party loans		4,674,493		2,434,733
<b>Total current liabilities</b>		<b>5,589,958</b>		<b>3,668,465</b>

**LONG-TERM LIABILITIES**

Stock settlement obligation 2,836,538 2,836,538

**Total liabilities** 8,426,496 6,505,003**COMMITMENTS AND CONTINGENCIES**

(Note 6)

-

-

**STOCKHOLDERS' EQUITY (DEFICIT)**Preferred stock, no par value, 1,000,000 shares  
authorized,

Edgar Filing: NANOBAC PHARMACEUTICALS INC - Form 10QSB

no shares issued and outstanding	-	-
Common stock, no par value, 250,000,000 shares authorized, 2006: 193,973,426 shares issued and outstanding		
2005: 189,006,760 shares issued and outstanding	16,484,550	16,307,050
Additional paid-in capital	3,669,231	3,503,681
Accumulated deficit	(20,490,865)	(17,380,535)
Accumulated other comprehensive income	9,127	34,525
<b>Total stockholders' equity (deficit)</b>	<b>(327,957)</b>	<b>2,464,721</b>
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>	<b>\$ 8,098,539</b>	<b>\$ 8,969,724</b>

The accompanying notes are an integral part of these financial statements.

## NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED  
STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months ended September 30, 2006	Three Months ended September 30, 2005	Nine Months ended September 30, 2006	Nine Months ended September 30, 2005
<b>REVENUE</b>	\$ 23,894	\$ 130,394	\$ 222,745	\$ 450,247
<b>COST OF REVENUE</b>	11,286	47,085	79,104	149,384
<b>GROSS PROFIT</b>	12,608	83,309	143,641	300,863
<b>OPERATING EXPENSES</b>				
Selling, general and administrative	273,813	278,199	974,972	888,716
Research and development	357,296	264,503	1,142,634	858,765
Impairment loss on intangible asset	-	-	585,000	-
Depreciation and amortization	117,860	189,462	423,888	567,188
<b>Total Operating Expenses</b>	748,969	732,164	3,126,494	2,314,669
<b>OPERATING LOSS</b>	(736,361)	(648,855)	(2,982,853)	(2,013,806)
<b>OTHER INCOME (EXPENSES)</b>				
Interest expense	(52,847)	(20,866)	(137,355)	(43,380)
Loss on stock settlement obligation	-	-	-	(717,908)
Other, net	2,025	(4,192)	9,878	(48,509)
<b>LOSS BEFORE INCOME TAXES</b>	(787,183)	(673,913)	(3,110,330)	(2,823,603)
<b>PROVISION FOR INCOME TAXES</b>	-	-	-	-
<b>NET LOSS</b>	\$ (787,183)	\$ (673,913)	\$ (3,110,330)	\$ (2,823,603)
<b>LOSS PER COMMON SHARE</b>				
Basic and Diluted	\$ 0.00	\$ (0.00)	\$ (0.02)	\$ (0.01)
<b>WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING</b>				
Basic and Diluted	193,599,067	189,006,759	192,795,771	188,700,715

The accompanying notes are an integral part of these financial statements.

## NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED  
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)  
(UNAUDITED)

	Common Shares	Stock Value	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Loss	Accumulated Other Comprehensive Income	Total
<b>Balance, December 31, 2005</b>	<b>189,006,760</b>	<b>\$ 16,307,050</b>	<b>\$ 3,503,681</b>	<b>(\$17,380,535)</b>		<b>\$ 34,525</b>	<b>\$ 2,464,721</b>
Stock issued for services	466,666	56,000	-	-	-	-	56,000
Stock issued for conversion of liabilities	4,500,000	121,500	-	-	-	-	121,500
Stock options issued for services	-	-	165,550	-	-	-	165,550
Comprehensive loss:							
Net loss	-	-	-	(3,110,330)	(\$3,110,330)		(3,110,330)
Foreign currency translation adjustment	-	-	-	-	(25,398)	(25,398)	(25,398)
Comprehensive loss					(\$3,135,728)		
<b>Balance, September 30, 2006</b>	<b>193,973,426</b>	<b>\$ 16,484,550</b>	<b>\$ 3,669,231</b>	<b>\$ (20,490,865)</b>		<b>\$ 9,127</b>	<b>\$ (327,957)</b>

The accompanying notes are an integral part of these financial statements.

## NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED  
STATEMENTS OF CASH FLOWS  
(UNAUDITED)

	Nine Months ended September 30, 2006	Nine Months ended September 30, 2005
--	--	---

**CASH FLOWS FROM OPERATING  
ACTIVITIES**

Net loss	\$ (3,110,330)	\$ (2,823,603)
Adjustments to reconcile net loss to cash flows from operating activities:		
Depreciation and amortization	423,888	567,188
Impairment loss on intangible asset	585,000	-
Loss on disposition of fixed assets	18,330	-
Loss on stock settlement liability	-	717,908
Charges for common stock issued for services	56,000	10,500
Interest expense accrued for stockholder loan	137,087	41,048
Net (increase) decrease in assets:		
Accounts receivable	(5,769)	(12,814)
Inventory	5,172	2,613
Other assets	6,170	21,758
Net increase (decrease) in liabilities:		
Accounts payable	13,021	(155,143)
Accrued compensation	(14,943)	(35,046)
Accrued expenses	(8,495)	(111,798)
Deferred revenue	(20,357)	15,400
Total adjustments	1,195,104	1,061,614
<b>Net cash flows from operating activities</b>	<b>(1,915,226)</b>	<b>(1,761,989)</b>

**CASH FLOWS FROM INVESTING  
ACTIVITIES**

Acquisition of furniture and equipment	(11,144)	(39,425)
Proceeds from sale of furniture and equipment	6,547	-
Payment of security deposit	(2,731)	-
<b>Net cash flows from investing activities</b>	<b>(7,328)</b>	<b>(39,425)</b>

**CASH FLOWS FROM FINANCING  
ACTIVITIES**

Proceeds from issuance of common stock pursuant to subscription agreements	-	200,000
Stock issuance costs	-	(30,373)
Proceeds from stockholder loans	2,102,673	1,604,551
Proceeds from notes payable	2,601	12,581
Payment of notes payable	(53,675)	(23,378)
<b>Net cash flows from financing activities</b>	<b>2,051,599</b>	<b>1,763,381</b>



<b>Effect of exchange rate changes</b>	(27,310)	32,297
Net change in cash	101,735	(5,736)
Cash balance, beginning of year	8,975	17,908
<b>Cash balance, end of year</b>	<b>\$ 110,710</b>	<b>\$ 12,172</b>

**Supplemental disclosures of cash flow information:**

Cash paid for interest	\$ 268	\$ 2,332
------------------------	--------	----------

**Supplemental schedule of non-cash investing and financing activities:**

Common stock and options issued in exchange for current liabilities	\$ 287,050	\$ -
---	------------	------

The accompanying notes are an integral part of these financial statements.

**NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**SEPTEMBER 30, 2006**  
**(UNAUDITED)**

**1. Nature of operations and summary of significant accounting polices**

**Nature of Business**

Nanobac Pharmaceuticals, Incorporated and subsidiaries, ("Nanobac", the "Company", or "NNBP") trades under the symbol "NNBP."

NNBP's primary business is research and development of therapeutic and diagnostic technologies related to nanobacterium sanguineum ("Nanobacteria"). Nanobacteria are believed to be small, calcifying nano-particles that can be found in human blood, kidney stones and arterial wall plaques.

**Principles of Consolidation**

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Nanobac Sciences LLC, Nanobac OY and Nanobac Research Institute LLC. All material intercompany transactions and balances have been eliminated in consolidation.

**Basis of Presentation**

In the opinion of management, the accompanying financial statements include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with generally accepted accounting principles. The results of operations for the nine months ended September 30, 2006 are not necessarily indicative of the results for a full year.

The financial statements for the period ended September 30, 2006 and notes thereto should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2005 for the Company as filed in the annual report on Form 10-KSB, which information is included herein by reference.

**Liquidity and Management Plans**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring losses and has a working capital deficiency at September 30, 2006. The Company is dependent on continued financing from outside investors including additional shareholder loans. All of these matters raise substantial doubt about the ability of the Company to continue as a going concern. Management believes that the Company will need to raise additional capital in order to launch new clinical trials, fund research and development for new treatment areas, and general working capital requirements. Capital may be raised through further sales of equity securities, which may result in dilution of the position of current shareholders. At this time, there is no firm commitment to invest in NNBP.

There can be no assurances that NNBP will be successful in obtaining debt or equity financing in order to achieve its financial objectives and continue as a going concern. The financial statements do not include any adjustments to the carrying amount of assets and the amounts and classifications of liabilities that might result from an adverse outcome of this uncertainty.



**NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**SEPTEMBER 30, 2006**  
**(UNAUDITED)**

**1. Nature of operations and summary of significant accounting polices (continued)**

**Stock Options**

In January 2006, the Company adopted the accounting provisions of Statement of Financial Accounting Standards No. 123R, "Share-based Payments" ("SFAS 123R"), replacing "Accounting for Stock-based Compensation" ("SFAS 123"), which are similar and require the use of the fair-value based method to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (warrants and options). The adoption of this standard had no significant impact on the Company's results of operations.

**Impairment of Long-lived Assets and Intangible Assets**

In accordance with Statement of Financial Accounting Standards No. 142, "Goodwill and Other Intangible Assets" ("SFAS No. 142"), and Statement of Financial Accounting Standards, No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" ("SFAS No. 144"), the Company reviews its non-amortizable long-lived assets, including intangible assets and goodwill for impairment annually, or sooner whenever events or changes in circumstances indicate the carrying amounts of such assets may not be recoverable. Other depreciable or amortizable assets are reviewed when indications of impairment exist. Upon such an occurrence, recoverability of these assets is determined as follows. For long-lived assets that are held for use, the Company compares the forecasted undiscounted net cash flows to the carrying amount. If it is determined that the long-lived asset will be unable to recover its carrying amount, then it is written down to fair value. For long-lived assets held for sale, assets are written down to fair value. Fair value is determined based on discounted cash flows of appraised values from management's estimates, depending upon the nature or the assets. Impairment within goodwill is tested using a two step method. The first step is to compare the fair value of the reporting unit to its book value, including goodwill. If the fair value of the unit is less than its book value, the Company then determines the implied fair value of goodwill by deducting the fair value of the reporting unit's net assets from the fair value of the reporting unit. If the book value of goodwill is greater than its implied fair value, the Company writes down goodwill to its implied fair value. There were no impairment adjustments recorded in 2005. As described in Note 3, during the nine months ended September 30, 2006, the Company's Product Rights intangible asset was deemed fully impaired based on the Company terminating the marketing and sales of dietary supplements and therefore the asset is not expected to be recoverable from the use or eventual disposition of the asset.

**Recent accounting pronouncements**

In June 2006, the Financial Accounting Standards Board ("FASB") announced a new interpretation, FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes" ("FIN 48"), which will be effective for fiscal years beginning after December 15, 2006. FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with FASB Statement No. 109, "Accounting for Income Taxes". FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company has not determined the impact of the adoption of FIN 48 on its consolidated financial statements.

**NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**SEPTEMBER 30, 2006**  
**(UNAUDITED)**

**1. Nature of operations and summary of significant accounting polices (continued)**

**Recent accounting pronouncements (continued)**

In February 2006, the FASB issued Statement of Financial Accounting Standards No.155, "Accounting for Certain Hybrid Financial Instruments - an amendment of FASB Statements no. 133 and 140" ("SFAS 155"), which is effective for fiscal years beginning after September 15, 2006. The statement was issued to clarify the application of FASB Statements No. 133 to beneficial interests in securitized financial assets and to improve the consistency of accounting for similar financial instruments, regardless of the form of the instruments. The Company has determined that the adoption of SFAS 155 will not have a significant impact on the consolidated financial statements.

In September 2006, the FASB issued Statement of Financial Accounting Standards No.157 "Fair Value Measurements" (SFAS 157"), which is effective for fiscal years beginning after November 15, 2007 and for interim periods within those years. This statement defines fair value, established a framework for measuring fair value and expands the related disclosure requirements. The Company is currently evaluating the potential impact of SFAS 157 on the consolidated financial statements.

**2. Related Party Transactions**

An entity controlled by the Chief Executive Officer (who is also the largest stockholder of NNBP), has loaned NNBP approximately \$4.7 million as of September 30, 2006. These loans bear interest at the rate of 5% per annum and are due on demand. Interest expense for the above loans for the three and nine months ended September 30, 2006 was approximately \$53,000 and \$137,000, respectively.

**3. Discontinuance of Product Line**

During March 2006, the Company's management established a plan for Nanobac to discontinue the sale of dietary supplements and the Company's focus to be exclusively on the science that will ultimately lead to drug discovery and the development of diagnostic products. Effective March 30, 2006, the Company assigned these product rights to an entity owned by the primary stockholder for no compensation. As a result of the above decision, a charge to earnings of \$585,000 for the impairment of the product rights intangible asset has been recognized in operating expenses in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2006.

**4. Abandonment of Lease**

During March 2006, the Company ceased occupying leased office space in Tampa, Florida. As a result of the early abandonment of this office lease, a charge to earnings of approximately \$125,000 for the write-off leasehold improvements and the acceleration of lease payments associated with the abandoned lease has been recognized in operating expenses and other expenses in the accompanying condensed consolidated statement of operations for the nine months ended September 30, 2006.

**NANOBAC PHARMACEUTICALS, INCORPORATED AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**SEPTEMBER 30, 2006**  
**(UNAUDITED)**

**5. Stockholders' Equity**

Effective July 1, 2006 the Company amended an employment agreement to settle a \$175,000 bonus that was due to the employee since January 31, 2006 through the issuance of 3,500,000 stock options with an exercise price of \$0.05 per common share, with immediate vesting. In accordance with SFAS No. 123(R), this grant was valued at approximately \$166,000 using the Black-Scholes valuation model and assuming a risk-free interest rate of 5%, volatility of 100% and an expected term of 60 months. The Stock option grant was approved by a corporate officer who has been provided this authority by the Board of Directors. In addition, the employment agreement provides for additional compensation in the form of stock options on an annual basis valued at \$225,000 plus bonus stock option grants of up to \$80,000 in equivalent stock for completion of specific research functions and reports through December 31, 2006. At September 30, 2006, the Company did not have a formal stock option plan for the above stock option issuances.

In July 2006, the Company entered into an agreement with Wall Street Resources, Inc. ("Wall Street") whereby Wall Street will provide the Company with written analytical coverage and reports and to advise and assist the Company in developing and implementing a business plan, strategy and objectives to present to the financial community. The agreement required the Company to issue 466,667 shares of common stock, valued at \$56,000, and pay \$15,000 cash to Wall Street upon the issuance of Wall Street's initial report, which was dated September 12, 2006. The agreement remains in effect through March 11, 2007.

## **Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations**

### **Business**

Nanobac Pharmaceuticals, Inc. and its subsidiaries (which may be referred to as “Nanobac”, “the Company”, “NNBP”, “we”, “us” or “our”) is a life science company dedicated to the discovery and developments of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (“CNPs”), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Nanobac's drug discovery and development efforts are focused on developing new and existing compounds that effectively inhibit, destroy or neutralize CNPs.

Calcification is a significant feature in most diseases that are leading causes of death, including heart disease. Calcification is shown in numerous studies to block circulation, cause inflammation and cell disruption, and is a sign of various cancers. We have decided to have a sharpened focus on drug therapy based on findings by Nanobac scientists that certain drugs, when combined, are effective at halting the calcification process. Some of these drug combinations have not been tested in animals or humans. However, the Company has an advantage in that each of these drugs on its own has an FDA-approved record of being safe; therefore regulatory hurdles are significantly lower in every national jurisdiction.

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)**

**Business (continued)**

Our plan is to focus on the following priorities over the next 12-18 months:

- **Therapy** - We are entering into agreements to test our proprietary drug combinations to treat stone-forming diseases, with a preliminary focus on prostatitis, which affects millions of men and currently is largely untreatable. We will also conduct tests with other stone forming diseases such as gallstones and kidney stones.
- **Infection** - The gold standard for proving that something is infectious is Koch's postulates. We intend to validate earlier findings on Koch's postulates with calcifying nanoparticles in laboratory animals, including testing whether the infection can be prevented or treated with a proprietary drug combination. In June 2006, a new study published by independent scientists in a peer reviewed journal demonstrated key elements of Koch's postulates by showing that CNPs are implicated in formation of black pigment gallstones in an animal model. In August 2006, we announced that we entered into an agreement to validate this finding with the same scientists including Dr. LiMin Wang from Shantou University Medical College, Guangdong, China, who will be the Principle Investigator
- **Characterization** - We have preliminary photographic and biochemical evidence that calcifying nanoparticles self-replicate in non-precipitating conditions, suggesting further that they have a self-sustaining mechanism and might be infectious. In a recent agreement with Fetzer Memorial Trust, we have begun experiments at our NASA laboratory in Houston to demonstrate this replication via time-lapse photography using award-winning CytoViva microscope technology capable of breaking through the 200 nanometer (nm) barrier for light microscopes. Our Scientific Director at NASA's Johnson Space Center has recently taken preliminary photographs of CNPs at magnifications that we believe had not been previously achieved. We own the intellectual property arising from the above experiments.
- **Thrombosis** - Thrombosis is the cause of death in most hemodialysis patients. We intend to validate findings that calcifying nanoparticles discovered in human blood provoke thrombosis and might be preventable.
- **Diagnostics** - We believe that our proprietary Elisa antibody test uniquely recognizes calcifying nanoparticles known as nanobacteria, and plan to further validate the functionality of this diagnostic test.

**Current Developments**- During September 2006, we announced our agreement with Mayo Clinic to study whether calcifying nanoparticles, already found in atherosclerotic plaque, are infectious and contribute to the onset of heart diseases

We will continue optimizing our proprietary diagnostics, with a clear focus on developing effective therapies in cooperation with well-established partners including NASA, Mayo Clinic, Cleveland Clinic, and numerous other institutions. Once these experiments are completed, we will have a compelling and well-rounded scientific basis for the Company to move forward.



**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)****Business (continued)**

**Patents** - We have filed applications for a number of patents, have been granted patents, and await prosecution of pending application in the US and International Stages.

Patent		General Subject Matter	Expiration Date
US 5,135,851	U.S.	-Method for the culture and detection of nanobacteria also known as calcifying nanoparticles (issued in 1992)	August 11, 2010
US 6,706,290	U.S. & International Application (PCT)	-Methods for the eradication of Nanobacteria from articles and animals using various novel combinations of systems, chemicals, compounds, drugs, prodrugs, supplements, etc. (issued in 2004)	Jul 6, 2018
PCT/EP1999/004555	U.S. & PCT Applications Filed	-Methods and Compositions (combinations) for treating diseases characterized by pathological calcification (Filed in 2004)	
	U.S. & PCT Applications Filed	-Methods and combinations of compositions including Bisphosphonates, chelators, and citrates (Filed in 2004)	
	U.S.	-Methods for the treatment of disease associated with calcification and/or plaque formation (Filed in 2004)	
	U.S. & PCT Application Filed	-Detection of antibodies against compositions of conformationally changed proteins comprising calcium binding protein hydroxy apatite complexes and novel in vitro test methods (Filed in 2005)	
	U.S. & PCT Applications filed	-Methods and compositions to detect calcifying nanoparticles including the identification and quantification of proteins thereon and correlation to diseases thereof (Filed in 2005)	

There can be no assurance that our patents or pending applications will afford legal protection against competitors or provide significant proprietary protection or competitive advantage. In addition, our patents or pending applications could be held invalid or unenforceable by a court, or infringed or circumvented by others, or others could obtain patents that we would need to license or circumvent. Competitors or potential competitors may have filed patent applications or received patents, and may obtain additional patents and proprietary rights relating to proteins, small molecules, compounds, or processes competitive with ours. Additionally, for certain of our product candidates, competitors, or potential competitors may claim that their existing or pending patents prevent us from commercializing such product candidates in certain territories. Further, when our patents expire, other companies could develop new competitive products to our products.

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)**

**Patents (continued)** - Trade secret protection for our unpatented confidential and proprietary information is important to us. To protect our trade secrets, we generally require our staff members, material consultants, scientific advisors, and parties to collaboration and licensing agreements to execute confidentiality agreements upon the commencement of employment, the consulting relationship, or the collaboration or licensing arrangement with us. However, others could either develop independently the same or similar information or obtain access to our information.

**Results of Operations**

The following table presents the percentage of period-over-period dollar change for the line items in our Condensed Consolidated Statements of Operations for the three and nine month periods ended September 30, 2006 and 2005. These comparisons of financial results are not necessarily indicative of future results.

	Three months ended September 30,			Nine months ended September 30,		
	2006	2005	% Change	2006	2005	% Change
Revenue	\$ 23,894	\$ 130,394	-82%	\$ 222,745	\$ 450,247	-51%
Cost of revenue	11,286	47,085	-76%	79,104	149,384	-47%
Gross Profit	12,608	83,309	-85%	143,641	300,863	-52%
Gross Profit percentage	53%	64%		64%	67%	
Selling, general and admin	273,813	278,199	-2%	974,972	888,716	10%
Research and development	357,296	264,503	35%	1,142,634	858,765	33%
Impairment loss	-	-		585,000	-	
Depreciation and amortization	117,860	189,462	-38%	423,888	567,188	-25%
Operating loss	(736,361)	(648,855)	13%	(2,982,853)	(2,013,806)	48%
Other income (Expense)	(50,822)	(25,058)	103%	(127,477)	(809,797)	-84%
Net loss	(\$787,183)	(\$673,913)	17%	(\$3,110,330)	(\$2,823,603)	10%

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)****Revenue**

Revenue for the three and nine months ended September 30, 2006 and 2005 is summarized as follows:

	<b>Three months ended Sep 30,</b>		<b>Nine months ended Sep 30,</b>	
	<b>2006</b>	<b>2005</b>	<b>2006</b>	<b>2005</b>
Dietary Supplements	\$ -	\$ 101,338	\$ 122,495	\$ 363,652
Observation Rights	3,000	4,000	15,000	4,000
Diagnostic Products	20,894	25,056	85,250	82,595
	\$ 23,894	\$ 130,394	\$ 222,745	\$ 450,247

During March 2006, we terminated the marketing and selling of dietary supplements in order for the Company to focus exclusively on the science related to CNPs, which we plan to lead to drug discovery and the development of diagnostic products for the detection and treatment of CNP related diseases. Accordingly, we had no revenue from dietary supplements for the three months ended September 30, 2006. We expect no revenue from dietary supplements in future periods.

Revenue from observation rights was recognized over the agreement's 12-month term using the straight-line method. This term ended on August 31, 2006, accordingly, there will be no revenue from observation rights in future periods.

**Cost of Revenue**

Cost of revenue consists of direct materials, testing services and shipping.

**Gross Profit**

As a percentage of revenue, our gross profit ("gross margin") was 65% to 70% of revenue when we were selling dietary supplements. Our diagnostic product line has historically generated a gross profit margin of 40% to 50%. During October 2006, we announced our agreement with American Health Associates Clinical Laboratories to serve as the exclusive U.S. provider of our proprietary blood diagnostic tests. We do not anticipate a material impact on our future gross margins as a result of this agreement.

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)****Selling, General and Administrative**

Approximately 75% of selling, general and administrative ("SG&A") expenses are comprised of payroll and professional fees. The majority of professional fees are related to patents and public company expenses for audit, legal and investor relations. Other significant SG&A expenses include facility rental and insurance.

SG&A decreased to \$274,000 for the three months ended September 30, 2006 from \$278,000 for the three months ended September 30, 2005. This decrease of \$4,000 was attributable to a \$135,000 increase in professional fees connected with patents, consultants and accountants offset by a \$133,000 decrease in payroll related costs and \$6,000 decrease in other SG&A expenses. The higher professional fees and lower payroll reflect our shift to a research based company.

SG&A increased to \$975,000 for the nine months ended September 30, 2006 compared to \$889,000 for the nine months ended September 30, 2005. This increase is attributable to the abandoned lease described below offset by other net decreases in SG&A.

During March 2006, the Company ceased occupying leased office space in Tampa, Florida. As a result of the early abandonment of this office lease, a charge to earnings of approximately \$106,000 for the acceleration of lease payments associated with the abandoned lease has been recognized in the accompanying financial statements for the nine months ended September 30, 2006. An additional charge is included in other expense for the write-off of leasehold improvements.

**Research and Development**

For the nine months ended September 30, 2006 and 2005 research and development ("R&D") expenses consisted of the following types of expenses:

	Nine months ended September 30,	
	2006	2005
U.S. Payroll and medical directors	52%	60%
Finland payroll and laboratory	33%	31%
Research studies	11%	6%
Other	4%	3%
	100%	100%

For the three months ended September 30, 2006, R&D expenses increased to \$357,000 or by 35% compared to \$265,000 for the three months ended September 30, 2005. For the nine months ended September 30, 2006, R&D expenses increased to \$1.1 million or by 33% compared to \$859,000 for the nine months ended September 30, 2005. The increase was the result of greater payroll expenses and medical director costs as we have shifted our primary emphasis to R&D.

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)**

**Impairment loss on intangible assets**

During March 2006, we established a plan to discontinue the sale of dietary supplements. As a result of the above decision, the product rights' intangible asset was deemed fully impaired and an impairment loss of \$585,000 has been recognized during the nine months ended September 30, 2006.

**Depreciation and amortization**

Over 95% of depreciation and amortization are related to the amortization of intangible assets (primarily patents) acquired in the June 2003 acquisition of LABS and the November 2003 acquisition of OY. Amortization expense decreased for the three and nine months ended September 30, 2006 compared to the three and nine months ended September 30, 2005 as the amortization of product rights was eliminated due to the impairment of this intangible asset described above.

**Operating Loss**

Our operating loss increased to \$736,000 for the three months ended September 30, 2006 compared to \$649,000 for the three months ended September 30, 2005. Approximately \$45,000 of this increased loss was the result of the elimination of the dietary supplement business. In addition, R&D costs increased \$93,000 due to our increased focus on research initiatives. These increases were partially offset by a decrease in amortization expense of \$61,000.

Our operating loss increased to \$3.0 million for the nine months ended September 30, 2006 compared to \$2.0 million for the nine months ended September 30, 2005. The majority of the increase is attributable to the \$106,000 charge for the abandonment of our Tampa lease and the \$585,000 additional amortization expense for our product right's intangible asset due to our termination of marketing and selling of dietary supplements. We also experienced an increase in R&D expense for this period.

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)****Other income (expense)**

Other income (expense) for the three and nine months ended September 30, 2006 and 2005 is summarized as follows:

	<b>Three months ended Sep 30,</b>		<b>Nine months ended Sep 30,</b>	
	2006	2005	2006	2005
Interest expense:				
Stockholder loan	(\$52,807)	(\$20,385)	(\$137,087)	(\$41,048)
Other	(40)	(481)	(268)	(2,332)
Loss on stock settlement obligation	-	-	-	(717,908)
Loss on disposition of assets	-	-	(18,330)	-
Foreign exchange gain (loss)	1,197	(2,107)	25,435	(38,239)
Other, net	828	(2,085)	2,773	(10,270)
<b>Total</b>	<b>(\$50,822)</b>	<b>(\$25,058)</b>	<b>(\$127,477)</b>	<b>(\$809,797)</b>

The shares issued in connection with the 2005 and 2004 Subscription Agreement transactions are financial instruments with characteristics of both liabilities and equity and as such have been presented in the accompanying consolidated balance sheets as a liability. Changes in the liability were recorded as charges to the statement of operations as a loss on the stock settlement obligation for the nine months ended September 30, 2005.

Loss on disposition of assets is attributable to leasehold improvements in connection with the abandonment of our lease. Foreign currency gain results from exchange rate changes between the U.S. dollar and the Euro on intercompany advances between our U.S. subsidiary and our Finland subsidiary.

**Net Loss**

We are experiencing significant losses as we conduct research and development related to nanobacteria. We believe it will take significant time before we will earn meaningful revenue to offset our expenses and there is no assurance that we will be able to accomplish this goal. As a result of the losses, we are dependent on affiliates of our CEO and other investors to provide sufficient cash sources to fund our operations.

**Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)**  
**Liquidity and Capital Resources**

Since the United States Bankruptcy Court confirmed a plan of reorganization that allowed the Company to emerge from Chapter 11 during calendar 2002, the Company has financed its activities primarily through loans made by entities affiliated with our current Chief Executive Officer (referred to herein as "the CEO Affiliated Entities"). These loans were made as funding was needed and were extremely advantageous to the Company in that the amounts were funded as the Company needed financial infusions and allowed the Company to avoid the costs and distractions of attempting to raise these amounts from unrelated parties. It is unrealistic to believe that unrelated parties would have offered terms as generous as those obtained from the CEO Affiliated Entities, and it is also unlikely that any financing could have been obtained under any terms without the financing of the CEO Affiliated Entities. From time to time the CEO Affiliated Entities have agreed to allow a portion of the loan balances to be converted into shares of the Company's common stock. There is no obligation on the part of the CEO Affiliated Entities to make additional loans to the Company. The CEO Affiliated Entities are also under no obligation to convert any portion of the loan balances owed to it into additional shares of the Company's stock.

Since August of 2004, the Company has received \$1.4 million (net of \$125,000 of expenses) from three unaffiliated investors and one affiliate for shares of the Company's stock and an equal amount of warrants to acquire additional shares of the Company's stock. The exact number of shares to be issued is dependent upon the average closing bid price of the Company's stock on the five trading days immediately prior to the date on which a registration statement for these shares is declared effective. The purchase price of the shares is equal to the lesser of (1) \$.12 or (2) 52% of the average closing price described above. An additional \$1.5 million is to be received from these investors within five days of registering the common shares and warrants. A registration statement has not yet been declared effective for these shares and we do not know if and when a registration statement will be declared effective for these shares. Also there are no assurances that the SEC will declare a registration statement effective.

As of September 30, 2006, we had total assets of \$8.1 million of which only \$269,000 were current assets. At September 30, 2006, we had total current liabilities of \$5.6 million and a working capital deficit of \$5.3 million. \$4.7 million of the \$5.3 million working capital deficit is attributable to the related party loans from CEO Affiliated Entities described above.

Net cash used in operations for the nine months ended September 30, 2006 was \$1.9 million. The negative cash flow from operations reflects the \$3.1 million net loss for the period offset by non-cash charges of \$1.0 million for depreciation, amortization and impairment loss.

Net cash used by investing activities for the three months ended September 30, 2006 included \$11,000 for the purchase of fixed assets, \$3,000 for a security deposit offset by \$6,000 of proceeds from the sale of property and equipment to CEO Affiliated Entities at book value.

Net cash provided by financing activities for the three months ended September 30, 2006 was \$2.1 million, which is attributable to stockholder loans.

As noted above, cash from stockholder loans and capital contributions financed our negative cash flow from operations. We are dependent on raising additional funding necessary to implement our business plan. Should we not be successful in raising cash from our CEO and other investors, we are unlikely to continue as a going concern.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)

### Critical accounting policies

*Use of estimates* - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

### Forward Looking Statements

Our disclosure and analysis in this Form 10-QSB contains some forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 ("the Act"), that set forth anticipated results based on our plans and assumptions. From time to time, we also provide forward-looking statements in other materials we release to the public as well as oral forward-looking statements. Such statements give our current expectations or forecasts of future events; they do not relate strictly to historical and current facts. We have tried wherever possible to identify such statements by using words such as "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "will" and similar expressions in connection with any discussion of future operating or financial performance.

In light of the important factors that can materially affect results, including those set forth above and elsewhere in this report, the inclusion of forward-looking information herein should not be regarded as a representation by us or any other person that our objectives or plans will be achieved. We may encounter competitive, technological, financial and business challenges making it more difficult than expected to continue to market our products and services; competitive conditions within our industry may change adversely; we may be unable to retain existing key management and research personnel; our forecasts may not accurately anticipate market demand; and there may be other material adverse changes in our operations or business. Certain important factors affecting the forward looking statements made herein include, but are not limited to (i) accurately forecasting capital expenditures; (ii) obtaining new sources of external financing; (iii) successfully conducting experiments to support that CNPs are an infectious in accordance with Koch's postulates and (iv) successfully implementing and protecting our intellectual property. Assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and business developments, the impact of which may cause the Company to alter its capital expenditure or other budgets, which may in turn affect the Company's financial position and results of operations.



## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (continued)**

### **Quantitative and Qualitative Disclosures About Market Risk**

While most of our operations are conducted in the United States, we also operate a laboratory in Kuopio Finland. We face two risks related to foreign currency exchange: translation risk and transaction risk. Amounts invested in our Finland operations are translated into US Dollars at the exchange rates in effect at the balance sheet date. Since the functional currency of our Finland subsidiary is the local currency, foreign currency translation of the balance sheet is reflected as a component of stockholders' equity and does not impact operating results.

Our Finland subsidiary collects revenue and pays expenses in Euros, mitigating transaction risk. Revenues and expenses in Euros translate into varying amounts of US Dollars depending upon whether the US Dollar weakens or strengthens against the Euro. Therefore, changes in exchange rates may negatively affect the Company's consolidated revenues and expenses (as expressed in US Dollars) from foreign operations.

Currency transaction gains or losses are incurred on our US Subsidiary's intercompany advance to our Finland Subsidiary. We recognize a gain on the intercompany advance as the US Dollar weakens against the Euro and we recognize a loss when the US Dollar strengthens against the Euro.

The Company has not entered into any material amount of foreign currency forward exchange contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange rates.

### **Item 3: Controls and Procedures**

#### *Disclosure controls and procedures*

Under the supervision and with the participation of our management, including our Chief Executive Officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report, and, based on this evaluation, our Chief Executive Officer has concluded that these controls and procedures are effective.

Disclosure controls and procedures are our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

**Item 3: Controls and Procedures (continued)**

***Section 404 of the Sarbanes-Oxley Act of 2002***

Section 404 of the Sarbanes-Oxley Act of 2002 requires our report on Form 10-KSB for 2006 to include a report of management on internal control over financial reporting. Internal control over financial reporting, as defined under these rules, is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

In our report, we will be required, among other things, to assess the effectiveness of our internal control over financial reporting. The report must also disclose any material weaknesses in internal control over financial reporting identified by management, and if there are any material weaknesses, we must conclude that our internal control over financial reporting was not effective. A material weakness, under the applicable rules, is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

In conducting our ongoing assessment of its internal control over financial reporting to prepare for compliance with the requirements under Section 404 of the Sarbanes-Oxley Act, we have identified a lack of segregation of duties to be a potential material weakness in internal controls. Lack of segregation of duties is inherent to our company due to the small number of employees. Our assessment is still in process to determine if this situation is actually a material weakness or if there are any other material weaknesses.

***Changes in internal controls***

There were no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation.

**PART II - OTHER INFORMATION**

**Item 1: Legal Proceedings**

Except as described below, we know of no material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholders are an adverse party or has a material interest adverse to us.

On August 10, 2004, we were served with a civil action as filed in the Superior Court of Fulton County State of Georgia by Foltz Martin LLC and Openbook Learning Club, Inc. ("Foltz"). This suit alleges that the Company is liable for approximately \$67,000 of liabilities plus approximately \$11,000 interest for services performed by the plaintiffs for HealthCentrics, Inc. in 2003 and 2004. The Company owned 100% of HealthCentrics from December 2003 through March 2004 when HealthCentrics was sold by the Company to an affiliate. We do not believe that the Company is liable for the obligations of HealthCentrics.

On January 19, 2006, we were served with a civil action as filed in the Superior Court of Fulton County State of Georgia by EliteCorp Atlanta, LLC ("EliteCorp"). This suit alleges that the Company is liable for approximately \$318,000 of liabilities plus approximately \$110,000 interest for services performed by the plaintiffs for HealthCentrics, Inc. in 2003 and 2004. We responded to this action on February 17, 2006 and denied virtually all the allegations of EliteCorp. We do not believe that the Company is liable for the obligations of HealthCentrics.



**Item 2: Unregistered Sales of Equity Securities and Use of Proceeds**

From August 2004 through February 2005, we executed Subscription Agreements with three unaffiliated investors and one affiliated investor. These investors paid us 50% of the subscription price at execution and the remaining 50% is due within five days from the date that a registration statement is declared effective for the common shares that are being issued. In exchange for the cash consideration, we are to issue these investors shares of our common stock equal to the amount paid divided by the lesser of (a) \$0.12 or (b) fifty-two percent of the average closing bid price for our common stock for the five days immediately prior to the date on which a registration statement is declared effective (“The Fixed Price”). In addition, each of these investors will receive an equivalent number of warrants with expiration dates of five years from the date of issuance. One half of these warrants will be priced at 110% of the Fixed Price and the remainder will be priced at 150% of the Fixed Price. The minimum number of shares and warrants that will be issued under these Subscription Agreements (assuming a Fixed Price of \$0.12 per share) is as follows:

	Number of Shares	Per Share	Proceeds
<b>Common Stock:</b>			
Unaffiliated Investors	16,250,000	\$ 0.12	\$ 1,950,000
Affiliates	8,333,333	\$ 0.12	\$ 1,000,000
	24,583,333		\$ 2,950,000
<b>Warrants:</b>			
	Number of Warrants	Exercise Price	
Unaffiliated Investors	8,125,000	\$ 0.13	
Unaffiliated Investors	8,125,000	\$ 0.18	
Affiliates	4,166,667	\$ 0.13	
Affiliates	4,166,666	\$ 0.18	
	24,583,333		

As of September 30, 2006, proceeds of \$1,475,000 have been received and 12,297,667 unregistered shares had been issued under the above Subscription Agreements. The actual number of shares and warrants that ultimately will be issued under these Subscription Agreements may be substantially higher due to the variability of the Fixed Price. Based on our recent traded price of \$0.04 to \$0.09 per share, three to six times as many shares and warrants would be issued as described above. Further, if the Fixed Price is less than \$0.09 per share, we do not have sufficient authorized shares to issue the common stock and warrants required under the above subscription agreements. Our stockholders need to approve any increase in our authorized shares.

Each of these investors received their shares in reliance upon Section 4(2) of the Securities Act of 1933, because each of the holders was knowledgeable, sophisticated and had access to comprehensive information about us. At all relevant times we were a reporting company under the Securities Exchange Act of 1934 and there was readily available adequate current public information with respect to the Company.

A success fee was awarded to a broker for one of the above unaffiliated investor transactions in the form of 5-year warrants equal to 20% of the value of the transaction. These warrants have exercise prices equal to \$0.16 to \$0.22 per share for transactions completed to date. Future warrants issued under this agreement will have an exercise price equal to NNBP’s stock price on the date of closing. We estimate that 2 million warrants will be issued to this broker.

**Item 3: Defaults upon Senior Securities**

None.

**Item 4: Submission of Matters to a Vote of Security Holders**

None.

**Item 5: Other Information**

None

**Item 6: Exhibits and Reports on Form 8-K**

(a) The following exhibits are filed as part of this report:

Exhibit 31.1 - Certification to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer

Exhibit 31.2 - Certification to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer

Exhibit 32.1 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer

Exhibit 32.2 - Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer

(b) Reports on Form 8-K

None

24

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 6, 2006

NANOBAC PHARMACEUTICALS, INCORPORATED

By: /s/ John D Stanton

\_\_\_\_\_  
John D Stanton  
Chief Executive Officer

25

---

**Nanobac Pharmaceuticals, Incorporated**

**EXHIBIT INDEX**

<u>EXHIBIT</u> <u>NUMBER</u>	<u>DESCRIPTION</u>	<u>PAGE</u>
31.1	Certification to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer	27
31.2	Certification to Section 302 of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer	28
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Executive Officer	29
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 - Chief Financial Officer	30